Charles D. Blanke
About
Charles D. Blanke is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery.
According to data from OpenAlex, Charles D. Blanke has authored 292 papers receiving a total of 18.5k indexed citations (citations by other indexed papers that have themselves been cited), including 163 papers in Oncology, 133 papers in Pulmonary and Respiratory Medicine and 71 papers in Surgery. Recurrent topics in Charles D. Blanke's work include Colorectal Cancer Treatments and Studies (98 papers), Gastric Cancer Management and Outcomes (78 papers) and Gastrointestinal Tumor Research and Treatment (60 papers). Charles D. Blanke is often cited by papers focused on Colorectal Cancer Treatments and Studies (98 papers), Gastric Cancer Management and Outcomes (78 papers) and Gastrointestinal Tumor Research and Treatment (60 papers). Charles D. Blanke collaborates with scholars based in United States, Canada and Switzerland. Charles D. Blanke's co-authors include Margaret von Mehren, George D. Demetri, Michael C. Heinrich, Christopher L. Corless, Christopher D.�M. Fletcher, Burton Eisenberg, Heikki Joensuu, Jonathan A. Fletcher, Leonard B. Saltz and Malcolm J. Moore and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.
In The Last Decade
Charles D. Blanke
279 papers receiving 18.0k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Charles D. Blanke United States | 57 | 9.6k | 8.5k | 6.5k | 5.8k | 2.2k | 292 | 18.5k | ||
| John Zalcberg Australia | 54 | 8.0k 0.8× | 9.7k 1.1× | 2.9k 0.4× | 5.5k 0.9× | 3.0k 1.4× | 410 | 18.5k | ||
| Patrick Schöffski Belgium | 68 | 9.5k 1.0× | 9.6k 1.1× | 2.7k 0.4× | 3.2k 0.6× | 4.8k 2.2× | 510 | 19.4k | ||
| Peter W. T. Pisters United States | 93 | 17.6k 1.8× | 16.9k 2.0× | 4.2k 0.6× | 11.2k 1.9× | 1.5k 0.7× | 299 | 27.5k | ||
| Narikazu Boku Japan | 61 | 10.0k 1.0× | 8.1k 1.0× | 3.1k 0.5× | 6.3k 1.1× | 1.8k 0.8× | 541 | 15.3k | ||
| Daniel G. Haller United States | 68 | 9.2k 1.0× | 16.8k 2.0× | 1.7k 0.3× | 8.7k 1.5× | 2.6k 1.2× | 243 | 25.2k | ||
| Olivier Bouché France | 60 | 9.5k 1.0× | 18.6k 2.2× | 2.0k 0.3× | 8.0k 1.4× | 2.8k 1.3× | 418 | 25.3k | ||
| John S. Macdonald United States | 50 | 10.0k 1.0× | 11.8k 1.4× | 1.8k 0.3× | 7.5k 1.3× | 2.1k 1.0× | 173 | 20.3k | ||
| Atsushi Ohtsu Japan | 75 | 17.2k 1.8× | 14.2k 1.7× | 4.8k 0.7× | 9.9k 1.7× | 4.8k 2.2× | 526 | 26.9k | ||
| David P. Kelsen United States | 72 | 6.3k 0.7× | 8.9k 1.0× | 1.1k 0.2× | 4.2k 0.7× | 3.1k 1.4× | 292 | 14.6k | ||
| Isabelle Ray‐Coquard France | 64 | 5.5k 0.6× | 7.0k 0.8× | 2.3k 0.4× | 3.6k 0.6× | 2.8k 1.3× | 418 | 16.7k |
Countries citing papers authored by Charles D. Blanke
Since
Specialization
Citations
This map shows the geographic impact of Charles D. Blanke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles D. Blanke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles D. Blanke more than expected).
Fields of papers citing papers by Charles D. Blanke
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Charles D. Blanke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles D. Blanke. The network helps show where Charles D. Blanke may publish in the future.
Co-authorship network of co-authors of Charles D. Blanke
This figure shows the co-authorship network connecting the top 25 collaborators of Charles D. Blanke. A scholar is included among the top collaborators of Charles D. Blanke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles D. Blanke. Charles D. Blanke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Chae, Young Kwang, Megan Othus, Sandip Pravin Patel, et al.. (2025). A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort. Cancer Communications. 45(8). 976–986.
2.
Patel, Sandip Pravin, Young Kwang Chae, Shiruyeh Schokrpur, et al.. (2025). Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma. npj Precision Oncology. 9(1). 24–24.
3.
Battaglin, Francesca, Fang‐Shu Ou, Xueping Qu, et al.. (2024). HER2 Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405. Journal of Clinical Oncology. 42(16). 1890–1902.
4.
Chae, Young Kwang, Megan Othus, Sandip Pravin Patel, et al.. (2024). Abstract CT262: A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: sarcomatoid carcinoma of lung (cohort 11). Cancer Research. 84(7_Supplement). CT262–CT262.
5.
Reckamp, Karen L., Mary W. Redman, Konstantin H. Dragnev, et al.. (2024). SWOG S2302, PRAGMATICA-LUNG: A prospective randomized study of ramucirumab plus pembrolizumab (PR) versus standard of care (SOC) for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer.. Journal of Clinical Oncology. 42(16_suppl). TPS8657–TPS8657.
6.
Cheng, En, Fang‐Shu Ou, Alan P. Venook, et al.. (2024). Plant-based diet and survival among patients with metastatic colorectal cancer. JNCI Journal of the National Cancer Institute. 117(1). 169–179.
7.
Sutton, Thomas L., Kevin G. Billingsley, Alicia J. Johnson, et al.. (2024). Adjuvant imatinib in high‐risk resected gastrointestinal stromal tumors: Merely delaying the inevitable?. Journal of Surgical Oncology. 130(1). 40–46.
8.
Patel, Sandip Pravin, Megan Othus, Young Kwang Chae, et al.. (2023). A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Neoplasia. Clinical Cancer Research. 30(1). 33–38.
9.
Innocenti, Federico, Xueping Qu, Fang‐Shu Ou, et al.. (2023). DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations. Journal of Clinical Oncology. 42(4). 399–409.
10.
Lee, Seohyuk, Qian Shi, Pankaj Kumar, et al.. (2022). Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702. Journal of Clinical Oncology. 41(5). 1079–1091.
11.
Innocenti, Federico, Alexander B. Sibley, Amy S. Etheridge, et al.. (2020). Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance). Clinical Cancer Research. 27(1). 267–275.
12.
Guercio, Brendan J., Sui Zhang, Alan P. Venook, et al.. (2020). Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405. JNCI Cancer Spectrum. 4(3). pkaa024–pkaa024.
13.
Yuan, Chen, Kaori Sato, Bruce W. Hollis, et al.. (2019). Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance). Clinical Cancer Research. 25(24). 7497–7505.
14.
Bailey, Howard H., Linus Chuang, Nefertiti C. duPont, et al.. (2016). American Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer Prevention. Journal of Clinical Oncology. 34(15). 1803–1812.
15.
Corless, Christopher L., Karla V. Ballman, Cristina R. Antonescu, et al.. (2014). Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial. Journal of Clinical Oncology. 32(15). 1563–1570.
16.
Gordon, Michael A., Holly Gundacker, Jacqueline Benedetti, et al.. (2013). Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Annals of Oncology. 24(7). 1754–1761.
17.
Smalley, Stephen R., Jacqueline Benedetti, Daniel G. Haller, et al.. (2012). Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection. Journal of Clinical Oncology. 30(19). 2327–2333.
18.
Hubbard, Joleen M., David M. Thomas, Greg Yothers, et al.. (2012). Benefits and Adverse Events in Younger Versus Older Patients Receiving Adjuvant Chemotherapy for Colon Cancer: Findings From the Adjuvant Colon Cancer Endpoints Data Set. Journal of Clinical Oncology. 30(19). 2334–2339.
19.
Heinrich, Michael C., Charles D. Blanke, Christopher L. Corless, & Brian Druker. (2003). PDGF Receptors as Therapeutic Targets. The Indian Journal of Medical Research. 55(11). 1259–72.
20.
Blanke, Charles D., Cari J. Clark, Guido Tricot, et al.. (1995). Evolving pathogens in allogeneic bone marrow transplantation: Increased fatal adenoviral infections. The American Journal of Medicine. 99(3). 326–328.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by John Zalcberg Breakdown of academic impact, for papers by Patrick Schöffski Breakdown of academic impact, for papers by Peter W. T. Pisters Breakdown of academic impact, for papers by Narikazu Boku Breakdown of academic impact, for papers by Daniel G. Haller Breakdown of academic impact, for papers by Olivier Bouché Breakdown of academic impact, for papers by John S. Macdonald Breakdown of academic impact, for papers by Atsushi Ohtsu Breakdown of academic impact, for papers by David P. Kelsen Breakdown of academic impact, for papers by Isabelle Ray‐Coquard